Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Joint Bone Spine
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le mercredi 17 juillet 2019
Doi : 10.1016/j.jbspin.2019.06.008
accepted : 12 June 2019
Intradiskal Treatments for Active Degenerative Disk Disease

Johann Beaudreuil
 Services de Rhumatologie, Médecine Physique et de Réadaptation, Hôpital Lariboisière-Fernand-Widal, AP–HP, Université de Paris, 2, rue Ambroise-Paré, 75010 Paris, France 


Intradiskal steroid injections were first used 70 years ago. The initial failure of this treatment method can be ascribed to the absence of preclinical studies and of well-defined criteria for patient selection. Intradiskal calcifications were reported after triamcinolone hexacetonide or cortivazol injections, and proof of clinical benefits remained elusive. The concept of active degenerative disk disease (DDD) then emerged, and cases of incapacitating chronic low back pain with Modic I endplate changes were reported, leading to renewed interest in evaluating intradiskcal steroid injections. Prednisolone acetate was proven effective in providing short-term relief and was well tolerated in patients with incapacitating chronic low back pain and Modic I changes. This development highlights the importance of concomitant advances in identifying diagnostic entities and developing treatment strategies for patients with nonspecific low back pain.

The full text of this article is available in PDF format.

Keywords : Low back pain, Active degenerative disk disease, Modic I, Intradiskal injections

© 2019  Published by Elsevier Masson SAS.